On Air Now

Listen

Listen Live Now » 101.9 FM Sioux Falls, SD

Weather

Current Conditions(Sioux Falls,SD 57104)

More Weather »
54° Feels Like: 54°
Wind: NW 18 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Scattered Thunderstorms/Wind 47°

Tomorrow

Partly Cloudy/Wind 67°

Fri Night

Mostly Clear 39°

Alerts

Transition Therapeutics' Alzheimer's drug gets FDA fast-track status

(Reuters) - Canadian biopharmaceutical company Transition Therapeutics said the U.S. Food and Drug Administration granted a fast-track status to its Alzheimer's drug, sending its U.S.-listed shares up 33 percent in post-market trading.

A fast track designation by the FDA expedites regulatory review of drugs that aim to treat serious diseases and fill unmet medical needs.

The drug, ELND005, currently being tested in a mid-stage trial, treats neuropsychiatric symptoms such as agitation or aggression in Alzheimer's disease.

Transition Therapeutics said the drug appeared to decrease the emergence and severity of specific neuropsychiatric symptoms in a previous mid-stage study.

About 90 percent of Alzheimer's patients develop neuropsychiatric symptoms and up to 60 percent develop agitation over the course of their disease, the company said.

Ireland-based Elan Corp Plc is Transition's marketing and development partner.

Transition Therapeutics' Toronto-listed shares closed at C$3.15 on Wednesday.

(Reporting by Krithika Krishnamurthy in Bangalore; Editing by Sriraj Kalluvila)

Comments